All Genzyme News
Genzyme
| June 24, 2008 | Genzyme and Isis complete licensing of mipomersen | | June 17, 2008 | Genzyme Files Applications for Approval of Mozobil in the United States and Europe | | June 2, 2008 | Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients | | May 7, 2008 | Preliminary Results from Phase 2 Genzyme Study | | April 25, 2008 | FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen | | April 23, 2008 | Genzyme Reports Strong First-Quarter Growth | | April 22, 2008 | Genzyme to Build New R&D Center in Beijing | | April 21, 2008 | Genzyme Provides Update on Myozyme® Manufacturing | | April 14, 2008 | Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy | | March 19, 2008 | Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients | | March 10, 2008 | Genzyme Announces Presentation of New Positive Data on Carticel® | | March 6, 2008 | Genzyme Launches Renvela® in the U.S. for Dialysis Patients | | February 13, 2008 | Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year | | February 1, 2008 | University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program | | February 1, 2008 | Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration | | January 15, 2008 | Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic | | January 8, 2008 | Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue | | January 7, 2008 | Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen | | December 19, 2007 | Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™ | | December 17, 2007 | Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation | | December 13, 2007 | Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints | | December 5, 2007 | Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML | | December 4, 2007 | National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment | | November 13, 2007 | Genzyme Receives FDA Response Letter on Synvisc-One™ | | October 29, 2007 | Epicel™ Wins Marketing Approval for Severe Burn Victims | | October 25, 2007 | Genzyme and Sunway to Collaborate on Gene Therapy Program in China | | October 24, 2007 | Genzyme Reports Strong Earnings Growth in Third Quarter | | October 23, 2007 | Genzyme Launches Cholestagel® in Europe | | October 22, 2007 | Bioenvision Shareholders Approve Acquisition by Genzyme Corporation | | October 22, 2007 | FDA Approves Genzyme's Renvela™ for Dialysis Patients | | October 16, 2007 | Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease | | October 15, 2007 | Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis | | October 12, 2007 | Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease | | October 12, 2007 | Genzyme Recognized by Scientists as a Top Employer | | October 10, 2007 | Delaware Court Approves Bioenvision, Genzyme Joint Petition | | October 10, 2007 | Bioenvision and Genzyme File Petition in Delaware Court | | October 4, 2007 | Genzyme Receives Approval to Market Elaprase® in Japan | | September 27, 2007 | Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share | | September 26, 2007 | Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis | | September 20, 2007 | FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia | | September 18, 2007 | Genzyme Begins Major Expansion of Boston Manufacturing Facility | | August 29, 2007 | Genzyme Announces Publication of DCOR Study in Kidney International | | August 9, 2007 | Genzyme Announces Settlement of Lawsuit Concerning Consolidation of Tracking Stocks | | August 2, 2007 | Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint | | July 25, 2007 | Genzyme Reports Significant Earnings Growth in Second Quarter | | July 23, 2007 | Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases | | July 19, 2007 | Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin’s Lymphoma Meets Primary Endpoint | | July 16, 2007 | Genzyme Announces Positive Results from Carticel® Study at Major Sports Medicine Meeting | | July 10, 2007 | Genzyme Completes Tender Offer to Acquire Bioenvision, Inc. | | July 6, 2007 | Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea |
|
|
|
|
CONTACT INFORMATION: |
|
Genzyme Therapeutics Ltd,
Genzyme Biosurgery
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: 01865 405200
Fax: 01865 774172
Genzyme Therapeutics Ltd
Genzyme Europe Research
310 Cambridge Science Park
Milton Road
Cambridge
CB4 0WG
Tel: 01223 394000
Fax: 01223 394190
Genzyme Ltd
Genzyme Diagnostics
50 Gibson Drive
Kings Hill
West Malling
Kent
ME19 4AF
Tel: 01732 220022
Fax: 01732 220024
Genzyme Ltd
Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PB
Tel: 01440 703522
Fax: 01440 716269
Registered Office for Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Company Registration No. 4316333
Registered in England
Registered Office for Genzyme Ltd
37 Hollands Road
Haverhill
Suffolk
CB9 8PU
Company Registration No. 01556886 Registered in England |
|
|
|
Genzyme UK Home
